Yarrow Bioscience (YARW) Total Liabilities (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Total Liabilities came in at $1.2 million in Q1 2026, down 89.94% YoY from $12.3 million in Q1 2025, and down 48.39% on a QoQ basis from $2.4 million in Q4 2025.
Yarrow Bioscience (YARW) Total Liabilities (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 11 years of Total Liabilities data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Total Liabilities fell 89.94% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 89.94% YoY) and the FY2025 annual result came in at $2.4 million, down 83.84% from the prior year.
- Total Liabilities retreated to $1.2 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $14.8 million in Q4 2024 to a low of $1.2 million in Q1 2026.
- A 5-year average of $8.4 million and a median of $8.4 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities surged 65.58% — and 2026, when it tumbled 89.94%.
- Tracing YARW's Total Liabilities over 5 years: stood at $9.3 million in 2022, then decreased by 4.23% to $9.0 million in 2023, then jumped by 65.58% to $14.8 million in 2024, then sank by 83.84% to $2.4 million in 2025, then tumbled by 48.39% to $1.2 million in 2026.
- The last three Total Liabilities figures came in at $1.2 million (Q1 2026), $2.4 million (Q4 2025), and $5.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | 1.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Mn |
| Mar 31, 2026 | 1.24 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Jun 30, 2025 | 5.84 Mn |
| Mar 31, 2025 | 12.29 Mn |
| Dec 31, 2024 | 14.82 Mn |
| Sep 30, 2024 | 12.66 Mn |
| Jun 30, 2024 | 11.78 Mn |
| Mar 31, 2024 | 8.31 Mn |
| Dec 31, 2023 | 8.95 Mn |
| Sep 30, 2023 | 7.76 Mn |
| Jun 30, 2023 | 7.69 Mn |
| Mar 31, 2023 | 8.83 Mn |
| Dec 31, 2022 | 9.35 Mn |
| Sep 30, 2022 | 6.84 Mn |
| Jun 30, 2022 | 6.84 Mn |
| Mar 31, 2022 | 8.59 Mn |
| Dec 31, 2021 | 18.41 Mn |
| Sep 30, 2021 | 22.43 Mn |
| Jun 30, 2021 | 59.09 Mn |